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Abstract
Background: Besides being the effectors of native anti-tumor cytotoxicity, NK cells participate in T-
lymphocyte responses by promoting the maturation of dendritic cells (DC). Adherent NK (A-NK) cells
constitute a subset of IL-2-stimulated NK cells which show increased expression of integrins and the ability
to adhere to solid surface and to migrate, infiltrate, and destroy cancer. A critical issue in therapy of
metastatic disease is the optimization of NK cell migration to tumor tissues and their persistence therein.
This study compares localization to liver metastases of autologous A-NK cells administered via the
systemic (intravenous, i.v.) versus locoregional (intraarterial, i.a.) routes.
Patients and methods: A-NK cells expanded ex-vivo with IL-2 and labeled with 111In-oxine were injected
i.a. in the liver of three colon carcinoma patients. After 30 days, each patient had a new preparation of
111In-A-NK cells injected i.v. Migration of these cells to various organs was evaluated by SPET and their
differential localization to normal and neoplastic liver was demonstrated after i.v. injection of 99mTc-
phytate.
Results: A-NK cells expressed a donor-dependent CD56+CD16+CD3- (NK) or CD56+CD16+CD3+
(NKT) phenotype. When injected i.v., these cells localized to the lung before being visible in the spleen and
liver. By contrast, localization of i.a. injected A-NK cells was virtually confined to the spleen and liver.
Binding of A-NK cells to liver neoplastic tissues was observed only after i.a. injections.
Conclusion: This unique study design demonstrates that A-NK cells adoptively transferred to the liver
via the intraarterial route have preferential access and substantial accumulation to the tumor site.
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Background
Effector functions mediated by cells of the immune sys-
tem are thought to play a crucial role in the control of
tumor development and progression. However, it has
been difficult to distinguish the part played by individual
immune cell subsets in these processes. T cells that medi-
ate tumor-specific responses are generally considered to
be the major anti-tumor effectors. However, cells respon-
sible for mediating innate or natural immunity have been
recently recognized to also contribute to anti-tumor
defense. Extensive investigation of tumor growth and
metastasis in animal models suggests that NK cells are
early participants in the immune response and are partic-
ularly effective in eliminating blood-borne metastases
[1,2]. In contrast, T cells are the effector cells responsible
for specific, long-lasting immunity.
In addition to their direct anti-tumor functions [3-7], NK
cells can mobilize adaptive immune response [8] presum-
ably by promoting the maturation of dendritic cells (DC)
[9-14] and by providing them with antigenic material
derived from tumor cell lysis [15,16]. DC mediate both
protective and autoimmune responses, depending on
their maturational state and soluble factors present in the
tissue microenvironment [17,18]. In the liver, for exam-
ple, Kupffer cells and LSEC constitutively express the anti-
inflammatory cytokines, IL-10 and transforming growth
factor beta (TGF-β), while hepatocytes secrete IL-10 in
response to autocrine and paracrine TGF-β. These
cytokines could inhibit maturation of liver DC [19,20].
Therefore, delivery of NK cells to the liver milieu could
shift the balance from tolerogenic to immunogenic condi-
tions. The hypothesis we are entertaining is that NK cell-
mediated DC maturation in the liver could alter the sup-
pressive local environment, enhance immune responses,
and lead to the elimination of tumor cells metastasizing
to the liver.
The efficacy of adoptive immunotherapy of solid tumors
depends on the localization of therapeutic cells to tissues.
This in turn is influenced by the route of administration
and access of the cells to tumor. Liver metastases are solely
fed by the hepatic artery, and injection of chemotherapeu-
tic agents [21] and immune cells [22] via this route has
proven to be effective in controlling the spread of tumors
of the digestive tract, whose initial metastasis site is the
liver.
The success of adoptive immunotherapy is also critically
dependent on the migratory properties of the effector cells
and their ability to access tumor cells in situ. High expres-
sion levels of molecules belonging to the integrin and to
the human-leukocyte-function-associated antigen fami-
lies, namely LFA-1 and very late antigen (VLA)-4, which
interact with adhesion molecules on the tumor endothe-
lium, is a characteristic feature of activated NK cells [23].
NK cells have the ability to migrate to, infiltrate and kill
cancer cells in solid tumor tissues [24,25] and eliminate
established tumors and metastases. Based on their selec-
tive ability to rapidly (1–5 h) respond to 22 nM IL-2 by a
temporal adherence to solid surface, we have previously
defined subpopulations of NK cells, namely activated A-
NK cells, which constitute 4–30% of fresh peripheral
blood NK cells and are notably different from the non-
adherent IL-2 activated cells (NA-NK). A-NK cells produce
significant levels of the DC-maturating cytokines IFN-γ,
IL1-β and TNF-α and display potent anti-tumor activities
in vivo and in vitro [26].
Injection of A-NK cells into the hepatic artery may be an
ideal approach to treating tumors metastasizing to the
liver. Although this approach to therapy has been previ-
ously used, no formal evidence exists for the superior
tumor infiltrating capacity of intraarterially (i.a.)-deliv-
ered versus intravenously (i.v.)-delivered A-NK cells. Here
we compare in the same patient the efficiency of tumor
localization of ex vivo generated clinical grade A-NK cells
delivered via locoregional i.a. versus i.v. injections.
Patients, materials and methods
Protocol design and patient's characteristics
Three patients with colon carcinoma metastasizing to the
liver only were enrolled in this study, which was approved
by the Italian Ministry of Health and by the Ethical Com-
mittee of Turin Molinette's Hospital and the Piedmont
Region. Informed consent was obtained from all patients.
The patients' characteristics and previous therapy are
listed in Table 1. For delivery of A-NK cells, the hepaticar-
terialcatheter implanted for chemotherapeutical purposes
was used. At the time of A-NK-cell injection, all patients
had discontinued chemotherapy for at least one month.
No disease progression had occurred between the first
(i.a.) and the second (i.v.) A-NK administration. Patients
had 160 ml blood drawn twice for each of two A-NK cell
preparations.
Table 1: Patients' characteristics
Patient Sex/Age Pathology Site of metastasis Previous treatment
1 M/57 Colon carcinoma Liver 5FU/FUTR
2 M/62 Colon carcinoma Liver 5FU/FUTR
3 M/60 Colon carcinoma Liver 5FU/FUTRJournal of Translational Medicine 2006, 4:49 http://www.translational-medicine.com/content/4/1/49
Page 3 of 9
(page number not for citation purposes)
A-NK cell generation
Cells were generated for therapy under conditions con-
forming to current good manufacturing practice (GMP),
i.e., using animal-free serum components and reagents
approved for human therapy and accompanied by certifi-
cates of analysis (COA). PBMC were isolated from venous
blood by Ficoll-Hypaque (Lymphoprep, 1.077 g/ml;
Nycomed Pharma, Oslo, Norway) gradient centrifugation
and washed in RPMI 1640 (Gibco cat. No. 61870-028)
containing 1% (v/v) defibrinated autologous plasma
(DAP). The PBMC were suspended at the concentration of
1 × 107 cells/ml in RPMI 1640 containing 10% DAP, 100
U/ml penicillin, 2 mM L-glutamine, 3 mg/ml sodium
bicarbonate, Pen/strep (100 U/ml) (culture medium) and
5 mM phenylalanine methyl ester (PME) at 7.0–7.2 pH.
Following a 30 min incubation at RT to deplete mono-
cytes, cells were extensively washed in medium, counted
and suspended in the adherence medium supplemented
with 1 mM CaCl2, 1 mM MgCl2, 100 U/ml heparin and
6,000 IU/ml of rIL-2 (Chiron s.r.l., Siena, Italy), obtained
from the local Molinette's Hospital Pharmacy and desig-
nated for human use. After 3 h at 37°C in a 5% CO2
atmosphere non-adherent cells were removed by washing
(x3) with pre-warmed medium, and adherent cells (A-NK
cell precursors) were counted in four sample flasks with a
grid bottom and multiplied for the total number of cul-
ture flasks. A feeder layer consisting of rIL-2 (50 IU/ml)-
stimulated monocyte-depleted PBMC irradiated at 5,000
rads suspended in culture medium containing 1 × 106/ml
of Con A (10 μg/ml) and 6,000 IU/ml rIL-2 was added to
each flask. Cells were incubated for 15 days and were fed
every four days with rIL-2 (6,000 IU/ml) culture medium
to adjust cell density to 1.5 × 106/ml.
A-NK cell labeling and administration
A-NK cells were harvested, washed, counted and their
phenotype was determined. An aliquot was sent for steril-
ity analysis. The remaining cells were suspended in 20 ml
clinical grade 0.93% NaCl solution containing 25% DAP,
6,000 IU/ml rIL-2 and 37 MBq 111In-oxine (Altana
Pharma, Milan, Italy). A-NK cells were generated twice for
each patient and the same number of cells was labeled on
both occasions. After 15 min at room temperature cells
were washed twice in 0.93% NaCl saline containing 25%
DAP and 6,000 IU/ml rIL-2. The cell pellet was then sus-
pended in 10 ml 0.93% NaCl containing 20% human
albumin (clinical grade) and cells were injected i.a. After
30 days, A-NK cells were again administered, this time i.v.
Paracetamol(Acetaminophen) (Perfalgan, UPSA Lab,
Braine-l'Alleud, Belgium) (1 g) and 1 × 107 rIL-2 were
given s.c. 30 h before and 48 h after these injections. Each
patient was injected with the same number of labeled
cells, generated in separate cultures at each of the two time
points.
Evaluation of labeling efficiency
Labeling efficiency was defined as the ratio between free
and cell-bound tracer, evaluated in a gamma counter as
the cpm of radioactivity contained in the washing super-
natant and in the cell pellet.
A-NK cell migration evaluation
Planar whole-body and single-photon emission-com-
puted tomography (SPET) acquisitions were performed
by two-head gamma camera (VARICAM-ESCINT, General
Electric, Milwankee, WI, USA) equipped with "medium
energy" collimators for 111In, with 20% window and
energy peaks at 173 and 247 KeV. Planar whole-body
acquisitions were performed at 1,6,24,72 and 96 h and
SPET acquisitions at 6 and 96 h.
Localization of A-NK cells to liver metastases
To estimate the extent of the non-pathological liver paren-
chyma, patients were given an i.v. injection of 99mTc
Phytate (FITATEC) (AMERSHAM SORIN, Saluggia, Italy)
before A-NK cell administration. Liver images were
acquired after 10 min by the gamma camera equipped
with "low energy" collimator with 20% window and
energy peak at 140 KeV. 111In labeled A-NK images were
acquired by the gamma camera equipped with "medium
energy" collimators, as described above.
Phenotypic analysis of A-NK cells
A-NK cells were analyzed by flow cytometry on day fif-
teen. One million cells were incubated for 20 min at 4°C
with mouse anti-human simultest CD3FITC/
CD16.CD56PE or with γ1 FITC/γ2a PE isotype controls
(Becton Dickinson, San Jose, CA, USA). Flow cytometric
analysis was performed using a FACScan flow cytometer
CellQuest (v2.1q) software (Becton Dickinson).
Results
Growth and phenotypic characteristics of A-NK cells
In two cultures of A-NK cells generated for every patient,
very similar numbers of adherent cells were obtained.
However, the number of A-NK cells that expanded after
fifteen days of culture were strikingly different in the same
patient (Table 2). Phenotyping of the final products
showed a patient-specific prevalence of NKT
CD16+CD56+CD3+  (patient #1) or of NK
CD16+CD56+CD3- (patients #2 and #3) cells. This pheno-
type was observed early in culture and persisted through-
out the culture period (not shown).
NA-NK cell labeling efficiency and stability
The mean efficiency of labeling was 56% (range 42–67%)
(Table 2).Journal of Translational Medicine 2006, 4:49 http://www.translational-medicine.com/content/4/1/49
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Migration of A-NK cells to the liver
Migration of the i.a. injected A-NK cells and of i.v. injected
A-NK cells (after 30 days) were assessed by planar whole-
body scintigraphy and SPET. Fig. 1 shows the kinetics of
tracer accumulation after i.a. (A) and i.v. (B) injection in
the three patients. Very low tracer activity was observed in
the lung after i.a. injection, whereas liver labeling was
immediate (four-fold and two-fold the lung and spleen
labeling respectively) and was still evident at 96 h. Imme-
diate labeling of lung observed after i.v. injection became
evident at 24 h and declined thereafter. The representative
radioimaging of Fig. 2 illustrates differential progression
of 111In-labeled A-NK cells from lung to spleen to liver
during the observation time after i.a. (A) and i.v. (B) deliv-
ery (patient #2). In a 24 h axial section from this patient,
SPET showed preferential accumulation of radioactivity in
liver compared to spleen six hours after i.a. (Fig. 3A), but
not after i.v. (Fig. 3B).
Localization of A-NK cells to tumor nodules
99mTc phytate is transformed by chelation with serum cal-
cium in vivo into a microcolloid which is taken up by cells
of the reticulo-endothelial system, particularly Kupffer
cells. 99mTc phytate was given i.v. before A-NK cell delivery
to estimate the extent of normal liver parenchyma. 111In
radioactivity was then evaluated in 99mTc phytate-positive
and in 99mTc phytate-negative areas to assess the ratio
between tumor-involved and normal tissues. This ratio
was >3 for i.a., but remained virtually unchanged at 0.7
for i.v. (Fig. 4, mean ± SE of the values referred to the three
patients). A representative SPET image analysis performed
in patient #1 (Fig. 5) illustrates 99mTc phytate uptake (top)
and 111In radioactivity (bottom) after i.a. (Fig. 5A) or i.v.
(Fig. 5B) cell delivery. The 99mTc phytate-negative (cold)
areas identified by the arrows in Figs. 5A and 5B (top) are
positive for 111In in Fig. 5A (bottom), but not in Fig. 5B
(bottom). The image is consistent with the localization of
111In-labeled A-NK cells in the neoplastic hepatic nodule
after i.a., but not after i.v. administration.
Discussion
As the first metastatic site of gastric and colon cancer, the
liver is a critical check point for systemic disease progres-
sion. The liver is rich in immune cells, including DC pre-
cursors, NK cells and T lymphocytes. Generation of CD8+
tumor-specific T cells, which mediate anti-tumor
responses in the liver, is enhanced by activated NK cells,
which facilitate maturation of DC [8-14]. However, a sup-
pressive liver environment hampers functional matura-
tion of DC and the consequent activation of the adaptive
immune response. Therapy with activated NK cells can
therefore be envisaged as a means to breaking liver toler-
ance and to boosting antigen-specific anti-tumor
responses. The efficiency of adoptive cellular immuno-
therapy of cancer strongly depends on the type, number
and the route of delivery of effector cells that are expected
to reach malignant tissues after their transfer.
We demonstrate that ex vivo expanded A-NK cells effi-
ciently home to liver metastases and only accumulate
therein, when they gain direct access to the portal system.
This route may favor the localization and concentration of
immune effector cells in the tumor, since liver metastases
are fed with arterial blood. However, preferential localiza-
tion in the tumor is also likely to depend on the intrinsic
homing characteristics of the injected cells. NK cells have
a regulated expression of a number of integrins that may
play a role in their localization. In situ immunohisto-
chemical staining has shown NK-cell localization to the
red pulp of the spleen and the sinusoid regions of the
liver. Few NK cells are present in other solid organs and,
surprisingly, there are relatively few NK cells in lymph
nodes [27]. NK cells present in the liver sinusoids are stra-
tegically located to detect and kill arriving metastatic can-
cer cells, and their accumulation at this site is favored by
chemokine ligands present in the LSEC [28]. The LSEC
cytokine environment, with IL-2 produced by resident T
cells [29] and IL-15 and IL-12 produced by Kupffer cells
[30], might be expected to potentiate homing and cyto-
Table 2: Biological characteristics of injected A-NK
Patient. Injection 
Site
Blood ml PBMC1 Monocyte-
depleted1
Adherent 
cells2
Final A-LAK 
recovery3
CD16+CD5
6+CD3+ %
CD16+CD5
6+CD3- %
Labeled4 cells/
injection
Labeling 
efficiency
1 i.a. 160 1.2 × 108 8 × 107 6 × 106 5 × 108 56 13 5 × 108 58
i.v. 160 2.8 × 108 1.5 × 108 5 × 106 1.2 × 109 59 14 5 × 108 56
2 i.a. 160 1.2 × 108 8 × 107 3.2 × 106 1.6 × 109 12 69 5 × 108 62
i.v. 160 2.5 × 108 9 × 107 3.6 × 106 6 × 108 28 5 5  ×  1 0 8 67
3 i.a. 160 1.3 × 108 5 × 107 1 × 106 6 × 108 10 60 5 × 108 55
i.v. 160 1.3 × 108 8 × 107 5 × 106 2.3 × 109 12 69 5 × 108 42
1 Peripheral blood mononuclear cells (PBMC) and monocyte-depleted populations were obtained from blood as described in Material and Methods.
2 Cells obtained after incubation of monocyte-depleted cells in presence of the adhrence medium (Materials and Methods).
3 Number of A-NK cells recovered after fifteen days of cultures of adherent cells with rIL-2 and feeder cells as described in Materials and Methods.
4 A-LAK cells recovered on day fifteen were ajusted at the indicated number and labeled with 111In-oxine before being injected i.a. or i.v.Journal of Translational Medicine 2006, 4:49 http://www.translational-medicine.com/content/4/1/49
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In vivo migration of A-NK cells Figure 1
In vivo migration of A-NK cells. The same number of 111In-labeled A-NK cells were injected i.a. (A) and, after one month, i.v. 
(B). Organ distribution of radioactivity was monitored at the indicated times (X axis) by planar whole-body acquisition (Y axis). 
An earlier and greater migration of labeled cells was observed in the liver after i.a. administration. Counts are corrected for 
isotope decay and refer to the mean ± SE of the three patients.Journal of Translational Medicine 2006, 4:49 http://www.translational-medicine.com/content/4/1/49
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toxic functions of NK cells. Indeed, genes involved in NK-
cell homing, cytotoxicity and cytokine secretory functions
are overexpressed in hepatic NK cells compared to blood
NK cells [28], but their expression profile is similar to that
of IL-2-activated blood NK cells. It is, therefore, very likely
that the radioactivity detected in the metastatic areas of
the liver is due to interactions between labeled A-NK cells
and the tumor LSEC.
The ability of A-NK cells to penetrate the tumor tissue is
relevant to their potential use as carriers of anti-tumor
drugs and as direct killers of tumor cells. In experimental
in vivo tumor models, NK cells are more frequently found
to localize tumors which are also sensitive to NK cell kill-
ing in vitro [27]. Besides direct anti-tumor activities of NK
cells, their localization in the liver tumor area would be
important for the maturation of DCs, possibly through
the production of IFN-γ and other cytokines.
Representative planar whole-body images of organ migration of 111In-labeled A-NK after i.a. (A) and i.v. (B) injections (patient #2)
Figure 2
Representative planar whole-body images of organ migration of 111In-labeled A-NK after i.a. (A) and i.v. (B) injections 
(patient #2). 111In uptake was observed in the liver soon after the i.a. administration and persisted for up to 96 h.Journal of Translational Medicine 2006, 4:49 http://www.translational-medicine.com/content/4/1/49
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Two A-NK subsets predominated in our three patients
after a fifteen-day expansion: CD16+CD56+CD3+  in
patient #1 and CD16+CD56+CD3- in patients #2 and #3.
Adhesion to tissue cells expressing the relevant receptors is
the main property of these cells, and it is conferred,
among other molecules, by N-CAM, which is present on
NK cells and a subpopulation of NKT cells [31,32]. NKT
cells are the population best represented in the liver [33].
In our study, preferential 111In labeling of these A-NK sub-
populations (both NK and NKT cells) in the metastatic
compared to normal liver was observed.
We found a prompt localization of A-NK cells to the lung
after i.v. injection, as also shown by other in vivo studies
[24,25,35]. Transit of NK cells to the lung via the periph-
eral blood circulation is likely to play a surveillance role in
vivo, since radiolabeled tumor cells injected i.v. are eradi-
cated by NK cells before they enter the lung [27]. Radioac-
tivity detected in our study is most probably attributable
to cell-bound rather than to cell-free tracer for two rea-
sons. First, the absence of excretion of radioactivity over
the observation period (ref [25] and our data not shown)
indicates extended survival of injected A-NK cells. Second,
free tracer would not have been taken up by the tumor
and was not taken up after i.v. administration (Fig. 5B bot-
tom). The half-life of adoptively transferred NK cells is
about 7–10 days [36]. This is particularly true in the per-
missive environment of liver sinusoids.
Conclusion
We have performed an imaging study of the biodistribu-
tion of ex vivo activated, adoptively-transferred autologous
A-NK cells and demonstrated their differential localiza-
tion in normal hepatic parenchyma and liver metastases.
The unique opportunity offered by this study of compar-
ing different administration routes in the same patient,
allowed unambiguous demonstration that A-NK cells
localize to liver metastases only when injected locoregion-
ally. This finding has important implications for the
design of future immunotherapy protocols based on the
principle that autologous A-NK cells adoptively trans-
ferred to the liver via the arterial route have preferential
access and substantial accumulation to the tumor site.
Abbreviations
A-NK: adherent Natural Killer; i.v.: intravenously; i.a.:
intraarterially; LSEC: liver sinusoidal endothelial cells;
PME: phenylalanine methyil ester; cpm: counts per
minute; SPET: single-photon emission-computed tomog-
raphy.
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